TRINETRA › Sectors › Healthcare
Zota Health Care LImited (ZOTA) — share price, P/E and fundamentals
Zota Health Care LImited (NSE: ZOTA) closed at ₹1,324.00 on 30 Oct 2026, -13.0% over one year, against a 52-week range of ₹1,022.00 – ₹1,740.00.
In the quarter ended 30 Sept 2026 (consolidated, filed 28 Oct 2026) it reported revenue of ₹199 cr and a net loss of ₹26 cr, a -12.8% net margin; revenue grew 54.6% year on year.
No trailing P/E is published: trailing twelve-month earnings are negative (-113 cr), so a P/E has no meaning — a loss-making business is not 'cheap' at a negative multiple. Judge it on revenue growth, cash burn and funding instead.
From the balance sheet dated 30 Sept 2026: return on equity -16.4%, ROCE -10.1%, debt-to-equity 0.05, Piotroski F-score 3 of 9.
Against 66 Healthcare peers on NSE: Net margin higher than 2% of 64 sector peers; PBT margin higher than 2% of 64 sector peers; ROE higher than 2% of 64 sector peers.
Key figures
| Last close | ₹1,324.00 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -1.6% / +2.5% / -13.0% |
| 52-week low – high | ₹1,022.00 – ₹1,740.00 |
| Market capitalisation | ₹4,585 cr |
| Price / book | 7.33 |
| EV / EBITDA | 830.3 |
| TTM EPS | ₹-32.57 |
| TTM net profit | ₹-113 cr |
| Quarter revenue | ₹199 cr |
| Quarter net loss | ₹26 cr |
| Net margin | -12.8% |
| Revenue growth (YoY) | +54.6% |
| Profit growth (YoY) | -88.5% |
| Return on equity | -16.4% |
| ROCE | -10.1% |
| Debt / equity | 0.05 |
| Current ratio | 1.85 |
| Free cash flow | ₹-73 cr |
| Piotroski F-score | 3 / 9 |
| Average daily turnover (50 days) | ₹6.4 cr |
Against Healthcare peers
| Metric | ZOTA | Peer median | Percentile |
|---|---|---|---|
| Net margin | -12.83 | 12.89 | 2 |
| PBT margin | -13.60 | 17.68 | 2 |
| ROE | -16.35 | 13.87 | 2 |
| ROCE | -10.11 | 17.26 | 2 |
| Debt / equity | 0.05 | 0.11 | 42 |
| FCF margin | -19.68 | -0.87 | 13 |
| P/B | 7.33 | 6.02 | 63 |
| EV/EBITDA | 830.26 | 22.34 | 100 |
Questions
What were Zota Health Care LImited's latest quarterly results?
For the quarter ended 30 Sept 2026, Zota Health Care LImited reported revenue of ₹199 cr and a net loss of ₹26 cr (consolidated), filed with the exchange on 28 Oct 2026.
What is Zota Health Care LImited's ROE?
Return on equity is -16.4% based on the balance sheet dated 30 Sept 2026.
Does Zota Health Care LImited have debt?
Debt-to-equity is 0.05 on the balance sheet dated 30 Sept 2026.
What is ZOTA's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, ZOTA traded between ₹1,022.00 and ₹1,740.00.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Sept 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.